Compare CPSS & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CPSS | IPHA |
|---|---|---|
| Founded | 1991 | 1999 |
| Country | US | |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.3M | 169.6M |
| IPO Year | 2010 | N/A |
| Metric | CPSS | IPHA |
|---|---|---|
| Price | $8.33 | $1.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 14.3K | ★ 19.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $393,506,000.00 | N/A |
| Revenue This Year | $139.62 | $22.29 |
| Revenue Next Year | $10.58 | $43.90 |
| P/E Ratio | $14.13 | ★ N/A |
| Revenue Growth | ★ 11.79 | N/A |
| 52 Week Low | $6.67 | $1.63 |
| 52 Week High | $11.42 | $2.63 |
| Indicator | CPSS | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 42.56 | 44.33 |
| Support Level | $8.27 | $1.68 |
| Resistance Level | $9.20 | $1.86 |
| Average True Range (ATR) | 0.26 | 0.09 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 6.89 | 17.39 |
Consumer Portfolio Services Inc is a U.S based company operating in the specialty finance sector. Its business is to purchase and service retail automobile contracts originated by franchised automobile dealers and, to a lesser extent by select independent dealers in the United States in the sale of new and used automobiles, light trucks, and passenger vans. Through its automobile contract purchases, the company provides indirect financing to the customers of dealers having limited credit histories, low incomes, or past credit problems, who it refers to as sub-prime customers. It serves as an alternative source of financing for dealers, facilitating sales to customers.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.